Biohaven Pharmaceutical (NYSE:BHVN) downgraded by Piper Sandler to “Neutral”

Biohaven Pharmaceutical (NYSE: BHVN – Get an assessment) was downgraded by Piper Sandler research analysts from an “overweight” rating to a “neutral” rating in a report released Thursday, Fly reports.

Several other stock analysts also commented on BHVN. HC Wainwright downgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a Wednesday, May 11 research report. SVB Leerink downgraded shares of Biohaven Pharmaceutical from an “outperforming” rating to a “market performance” rating and set a target price of $150.00 for the stock. in a research note from Wednesday, May 11. Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a Wednesday, May 11 research note. Finally, Wedbush downgraded shares of Biohaven Pharmaceutical from an “outperforming” rating to a “neutral” rating and set a target price of $148.50 for the stock. in a Monday August 8 research note. Six research analysts gave the stock a hold rating and two gave the stock a buy rating. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $157.17.

Biohaven Pharmaceutical Stock Performance

BHVN stock traded down $0.02 during Thursday’s trading, hitting $148.03. 3,987 shares of the company were traded, compared to its average volume of 529,230. Biohaven Pharmaceutical has a 52-week low of $79.01 and a 52-week high of $151.51. The company has a fifty-day simple moving average of $145.73 and a 200-day simple moving average of $131.52. The stock has a market capitalization of $10.58 billion, a price-earnings ratio of -9.99 and a beta of 1.03.

Institutional entries and exits

Institutional investors have recently increased or reduced their stake in the stock. US Bancorp DE increased its position in Biohaven Pharmaceutical by 19.1% in Q1. US Bancorp DE now owns 586 shares of the company valued at $70,000 after purchasing an additional 94 shares during the period. Montag A & Associates Inc. increased its position in Biohaven Pharmaceutical by 16.7% during the 4th quarter. Montag A & Associates Inc. now owns 804 shares of the company valued at $111,000 after purchasing an additional 115 shares during the period. Victory Capital Management Inc. increased its position in Biohaven Pharmaceutical by 6.4% in Q1. Victory Capital Management Inc. now owns 2,564 shares of the company valued at $229,000 after purchasing an additional 155 shares during the period. Washington Trust Advisors Inc. increased its position in Biohaven Pharmaceutical by 24.6% in Q1. Washington Trust Advisors Inc. now owns 810 shares of the company valued at $96,000 after purchasing an additional 160 shares during the period. Finally, Palladiem LLC increased its position in Biohaven Pharmaceutical by 10.5% during the 2nd quarter. Palladiem LLC now owns 1,895 shares of the company valued at $276,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors hold 88.03% of the company’s shares.

About Biohaven Pharmaceutical

(Get an assessment)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Articles

The Fly logo

Analyst Recommendations for Biohaven Pharmaceutical (NYSE: BHVN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Biohaven Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.

While Biohaven Pharmaceutical currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here